ArticleTranslational neuroscience2017
Caffeoylquinic Acid Enhances Proliferation of Oligodendrocyte Precursor Cells.
Article in Translational neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Inhibition of ADORA3 promotes microglial phagocytosis and alleviates chronic ischemic white matter injury.CNS neuroscience & therapeutics · 2024Article
- Adrenomedullin: an important participant in neurological diseases.Neural regeneration research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report evaluates the protective effect of caffeoylquinic acid (CA) injury to oligodendrocyte precursor cells (OPCs) by promoting the formation of oligodendrocytes. Neonatal rat brain was used to isolate primary OPCs and non-lethal CoCl2 was used to induce hypoxic stress to inhibit the differentiation of OPCs. Differentiation of OPCs was estimated by survival assay and the expressions of myelin-basic-protein (MBP). Moreover, the effect of CA on the Akt signanling pathway was also estimated in the presence and absence of LY294002 (PI3K/Akt inhibitor) and adrenomedullin (AM) receptor antagonist (AM22-52) by using western blot assay. It was observed that CA enhances the differentiation OPCs in CoCl2 induced hypoxic stress condition. However treatment with CA in presence of LY294002 and AM22-52 was not able to enhance the differentiation of OPCs. Moreover treatment with CA significantly enhances the phosphorylation of Akt and presence of LY294002 and AM22-52 inhibits it. This report concludes that CA effectively attenuates the injury of white matter (OPCs) by enhancing the differentiation of OPCs. It enhances the formation of oligodendrocytes by activating AM receptor and thereby accelerates the regeneration of neuron in pathological condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.